Registration number: SC387999

OracleBio Limited

Contents

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 7

OracleBio Limited

Company Information

Directors

Dr Lorcan Sherry Dr John Waller

Registered office

Maclay Murray & Spens LLP 1 George Square Glasgow G2 1AL

Bankers

The Royal Bank of Scotland Glasgow City Branch 10 Gordon Street Glasgow G1 3PL

Accountants

AIMS Accountants for Business Chartered Management AccountantsBroom Cottage 53 Grange Road Alloa Clackmannanshire FK10 1LU

OracleBio Limited

(Registration number: SC387999)
Balance Sheet as at 31 March 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	5	66,685	87,344
Current assets
Debtors	6	587,222	371,317
Cash at bank and in hand		1,089,287	292,670
		1,676,509	663,987
Creditors: Amounts falling due within one year	7	(594,574)	(369,218)
Net current assets		1,081,935	294,769
Total assets less current liabilities		1,148,620	382,113
Creditors: Amounts falling due after more than one year	7	-	(184,069)
Provisions for liabilities		(16,671)	-
Net assets		1,131,949	198,044
Capital and reserves
Called up share capital		2	2
Retained earnings		1,131,947	198,042
Shareholders' funds		1,131,949	198,044

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 24 December 2025 and signed on its behalf by:
 

......................................... Dr John Waller Director

OracleBio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1	General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
Maclay Murray & Spens LLP
1 George Square
Glasgow
G2 1AL
Scotland

The principal place of business is:
Biocity Scotland
Bo'Ness Road
North Lanarkshire
ML1 5UH

These financial statements were authorised for issue by the Board on 24 December 2025.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

OracleBio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Tax

The tax expense for the period comprises current tax and deferred tax.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Computer equipment and software	20% Straight line
Office Equipment	20% Reducing Balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

OracleBio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 28 (2024 - 25).

4

Taxation

Tax charged/(credited) in the income statement

	2025  £	2024  £
Current taxation
UK corporation tax	308,043	-
Deferred taxation
Arising from origination and reversal of timing differences	32,913	12,458
Tax expense in the income statement	340,956	12,458

OracleBio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

5	Tangible assets

	Furniture, fittings and equipment  £	Total £
Cost or valuation
At 1 April 2024	676,048	676,048
Additions	13,557	13,557
At 31 March 2025	689,605	689,605
Depreciation
At 1 April 2024	588,704	588,704
Charge for the year	34,216	34,216
At 31 March 2025	622,920	622,920
Carrying amount
At 31 March 2025	66,685	66,685
At 31 March 2024	87,344	87,344

6

Debtors

Current	2025 £	2024 £
Trade debtors	482,420	307,349
Prepayments	66,428	43,172
Other debtors	38,374	20,796
	587,222	371,317

7

Creditors

Creditors: amounts falling due within one year

	Note	2025 £	2024 £
Due within one year
Loans and borrowings		-	33,333
Trade creditors		28,136	54,236
Taxation and social security		303,006	39,657
Accruals and deferred income		185,624	54,571
Other creditors		77,808	187,421
		594,574	369,218

Creditors: amounts falling due after more than one year

OracleBio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

	Note	2025 £	2024 £
Due after one year
Loans and borrowings		-	184,069

8

Dividends

Final dividends paid

		2025 £		2024 £
Final dividend of £8.50 per each Ordinary share share		68,000		68,000

9	Related party transactions

Included within Other Creditors are loans of £68,919 from the Directors.